Summary During a clinical trial of duration of chemotherapy in small cell lung cancer (SCLC), 71 of 610 patients (11.6%) died in the first 3 weeks. Chemotherapy consisted of cyclophosphamide 1 gim-2 i.v. day 1, etoposide 100mg t.d.s. orally days 1-3, vincristine 2mg i.v. day 1. The time of death was found to be nonrandomly distributed within the first chemotherapy cycle, with a peak incidence between days 7 and 12 after chemotherapy. Patients were matched with controls who were the next cases entered into the study who did not die in the first 3 weeks. Patients dying early were more likely to have clinical hepatomegaly (P<0.0001), and ECOG score >1 (P<0.00001). As a group these patients also had a higher alkaline phosphatase (P<0.0002), an elevated blood urea (P<0.00001) and a lower serum albumin (P<0.0001) than controls. It is probable that infection contributes to the death of these already ill patients at a time when the blood count is low. Early deaths have been noted in two other large trials using regimens including etoposide. Prophylactic antibiotics or dosage modification may prevent the early death of these high risk patients.
In unselected series of cases of SCLC ar patients have extensive disease at the tim treated (Souhami et al., 1984 ; Osterlind patients have a less than 2% 2-year su survival of 8-10 months (Feld et al., I these patients is with chemotherapy palliative -to relieve symptoms and to ] possible. In some large chemotherapy curves sometimes show an abrupt decli treatment (Hirsch et al., 1987; MRC Lt Party, 1989) . We noticed a similar analysing the results of a recently com chemotherapy duration in SCLC of pre stage (Figure 1 ). The present report ana biochemical factors associated with e demonstrates that these patients can be i high risk before treatment begins. Patients (P) who died in the first 3 weeks were identified and clinical and biochemical parameters, recorded at presentation, were compared with a control group (C) who consisted of the next patient entering the study who did not die in the first 3 weeks. The clinical features examined were performance status (PS) using the ECOG score; disease extent; presence or absence of SVC obstruction; palpable lymphadenopathy; palpable hepatomegaly; and bone scan evidence of metastases. Of these parameters, PS and disease extent were recorded on the computer data base as part of the registration details. The other clinical data were collected from the case notes. It is for this reason that the comparison is made with a control group of equal size rather than with the entire trial. For those parameters recorded on the trial registration forms the data are given for both the control group and the entire trial. Plasma urea, alkaline ts in the randomised phosphatase, sodium and albumin were also compared since these factors had previously been shown to have prognostic significance in other studies (Souhami et al., 1985 Table I . The patients dying early had similar median ages and age ranges, and similar sex ratio as the controls and the entire study group. There were more patients with extensive disease in the group dying early than in the controls (P= 0.05). The day of death in the first chemotherapy cycle was analysed and found to be non-randomly distributed (Figure 2) . The highest death rate was during the period 7-12 days after the administration of chemotherapy, which coincides with the expected nadir of the white blood count. Nadir counts were not performed as a routine in this study, so no direct comparison of blood counts in patients and controls can be made. Apart from disease extent two other clinical factors were strongly predictive for early death. These were poor PS (P<0.00001, Figure 3) , and palpable hepatomegaly (P vs. C=61% vs 23%, P<0.0001). Palpable lymphadenopathy was present in 28.9% of patients, abnormal bone scan in 50% and SVC obstruction in 11.5% with no difference between patients and controls.
In patients dying early the mean percentage of upper limit of alkaline phosphatase was 235.5% compared with 115.9% in the controls (P <0.0002, Table II ). The distribution of values is shown in Figure 4 . The mean serum albumin was 81.1% of the mean of the normal range in the patients and 90.0% in the controls (P<0.00005). The distribution of these values is shown in Figure 5 . The mean blood urea (Figure 6 ) was 175.1% of the mean of the normal range in the patient group compared with 107.3% in the controls (P= <0.00001). The mean plasma sodium (Table II) was slightly lower in the early death group than in controls. in these patients. In the study of Hirsch et al. (1987) The data presented here show that chemotherapy-induced toxicity is almost certainly playing a part in these early deaths. The maximum death rate at the period corresponding to the onset of neutropenia is unlikely to have another explanation. The demonstration of the non-random distribution of the time of death can only be made in very large studies. These analyses have been repeated using the data of the UK Medical Research Council trial (1989) and the cycle-related mortality has been confirmed in that large study. Our data showed only a slight increase in number of deaths in the second and subsequent cycles, implying that the high risk patients mostly succumbed during the first cycle. It is worth noting that many of these very sick patients are often considered by their family practitioner to have died from cancer and that the contribution of chemotherapy to toxicity might therefore be underestimated in conventional reporting of toxicity.
Our data clearly show the hepatic metastasis is strongly associated with an increased risk of early death. Clinical hepatomegaly and abnormal liver enzyme tests were very significantly more frequent in patients than in controls. Abnormal liver function tests are known to be associated with altered pharmacokinetics of intravenous etoposide. The area under the plasma concentration curve is higher in patients with a raised alkaline phosphatase or with reduced plasma albumin (Pfluger et al., 1987; Arbuck et al., 1985) . The volume of distribution in steady state is inversely correlated to the level of plasma albumin (Pfluger et al., 1987) . These results support the interpretation of the present results as being in part due to increased susceptibility to the toxicity of etoposide in patients with abnormal hepatic function. The effect of abnormal liver function on the absorption distribution and metabolism of oral etoposide is not known, but oral administration is associated with considerable variation in bioavailability (Arbuck et al., 1985) which may make toxicity less predictable. The fi serum half life of vincristine is prolonged in patients with abnormal liver function (Van den Berg et al., 1982) , but this drug is not associated with a degree of myelosuppression which would contribute greatly to infection. Cyclophosphamide is converted to its active metabolite by the liver and abnormal liver function prolongs the half life of the parent, noncytotoxic, compound (Juma, 1984) .
The contribution of a raised blood urea to early death might be explained by decreased clearance of etoposide from the circulation in patients with impaired renal function as shown by Sessa et al. (1985) . The causes of the raised blood urea in our patients are not known with certainty but it seems possible that some of the iller patients had a pre-renal cause such as salt and water depletion.
The analysis shows that the patients at risk with this regimen can be identified and a strategy adopted to avoid infection such as reduction of the dose in the first cycle.
Alternatively we recommend that, if these high risk patients receive a full dose of chemotherapy containing etoposide on the first cycle, a nadir blood count is obtained and consideration given to prophylactic antibiotics in those patients who are neutropenic after the first cycle. It is probably prudent to obtain nadir blood counts in further cycles and to adjust subsequent doses in severely neutropenic patients. Further studies on the pharmacology of oral and intravenous etoposide in these patients would be very helpful in trying to elucidate the pharmacological reasons for the toxicity. 
